ArticleApplied microbiology and biotechnology2026
Aloe emodin disrupts Candida albicans mitochondrial iron homeostasis against its hyphal development and oral candidiasis.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A novel antibacterial-immunomodulatory injectable hydrogel for periodontitis management: an in vitro study.BMC oral health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Candida albicans, a critical pathogen listed on the WHO fungal priority pathogens list, is a major cause of candidiasis and candidemia, particularly in immunocompromised populations. The lack of novel antifungal drugs and the increasing prevalence of drug resistance underscore the urgent need for new therapeutic strategies. By screening compounds derived from Aloe vera using hyphal induction assays, we identified aloe emodin (AE) as a potent inhibitor of C. albicans hyphal development. We demonstrate for the first time that AE, at concentrations of 50-100 μg/mL that do not affect fungal growth, significantly inhibits C. albicans hyphal development and its infections to oral epithelial cells without cytotoxicity. The confocal observation and following transcriptome and metabolome analysis demonstrate that AE localizes to fungal mitochondria and chelates iron, thereby disrupting iron homeostasis. These effects lead to mitochondrial dysfunction and metabolic reprogramming, particularly by impairing succinate dehydrogenase 2 activity, thereby reducing ATP and cAMP production. The decrease in cAMP levels leads to downregulation of the cAMP-PKA signaling pathway, a central regulator of hyphal development, ultimately suppressing hyphal growth. Mitochondrial function and metabolic assays, together with validation using mutants of the cAMP-PKA pathway, further confirmed the mechanism underlying the anti-hyphal activity of AE. AE at 50-100 μg/mL administered via drinking water also significantly reduced fungal burden and tissue damage in an oropharyngeal candidiasis model, which is similar with clinical antifungal nystatin. Collectively, our findings indicate that AE is a promising candidate for development as a therapeutic agent for oral candidiasis. KEY POINTS: • Aloe emodin disrupts mitochondrial iron homeostasis to remodel metabolism in C. albicans. • Aloe emodin downregulates the cAMP-PKA pathway to inhibit C. albicans hyphae. • Aloe emodin functions as a novel candidate for treating infections caused by C. albicans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.